Efbemalenograstim Alfa-Vuxw

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 5 publications

Granulocyte colony-stimulating factor-induced hypersensitivity reaction with leukocytosis in a pediatric germ cell tumor patient: a case report.

Granulocyte colony-stimulating factor-induced hypersensitivity reaction with leukocytosis in a pediatric germ cell tumor patient: a case report.

Journal: Frontiers in pediatrics

Published: November 19, 2025

Ryzneuta for prevention of febrile neutropenia.

Ryzneuta for prevention of febrile neutropenia.

Journal: The Medical letter on drugs and therapeutics

Published: August 13, 2024

Efbemalenograstim Alfa-vuxw.

Efbemalenograstim Alfa-vuxw.

Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Published: June 09, 2024

Efbemalenograstim Alfa: First Approval.

Efbemalenograstim Alfa: First Approval.

Journal: Drugs

Published: June 27, 2023

A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer.

A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer.

Journal: BMC cancer

Published: March 29, 2023

Showing 1-5 of 5

Last Updated: 09/26/2026